USAN Council's statement on the use of USAN as domain names is that a name published by the United States Adopted Names (USAN) Program in the USP Dictionary of USAN and International Nonproprietary Names, and on the United States Adopted Names website shall be the effective equivalent of an intellectual property right for the relevant entities.
Visit United States Adopted Names FAQ to learn more.
Comments or protests should be addressed to Stephanie Shubat, USAN program director, American Medical Association, 330 North Wabash Ave., Suite 39300, Chicago, Illinois 60611, or via email: [email protected].
In order to ensure your "under consideration" USAN domain name is available, you should consider purchasing the .com, .net and .org domain names of the USAN under consideration. The optimal time to do this is when you receive the letter from the USAN Program informing you of the USAN Council's naming decision.
The following names for the drugs described are "under consideration" by the USAN Council:
October 2026
Cimlespagene parvec: Treatment of Spastic Paraplegia Type 50 (SPG50)
Delpacibart zotadirsen: Treatment of muscular dystrophy diseases
Ferucadextran: MRI Contrast Agent
Inatovtabart: Antineoplastic, treatment of advanced or metastatic urothelial carcinoma
Izovocabgene geleucel: Treatment of autoimmune disorders
Lumonistrocel: Treatment of spinocerebellar degeneration (SCD), also called spinocerebellar ataxia (SCA)
Nelvutamig: Treatment of advanced solid tumors
Nenocorilant: Treatment of solid tumors
Pabinafusp alfa: Mucopolysaccharidosis type II (MPS II, Hunter Syndrome)
Reltodecacog alfa: Restoring coagulation by bypassing factor Xa inhibitor-mediated anticoagulation
Silmoretgene parvec: Treatment of AIPL1-related inherited retinal dystrophy (AIPL1-IRD)
Simgotindeg: Antineoplastic, treatment of solid tumors
Tifeglipron: Glycemia control and weight loss in overweight and obese patients
Zacamecgene parvec: Treatment of Rett syndrome
Zaloganan: Treatment of periprosthetic joint infection (PJI)
Zaloganan acetate: Treatment of periprosthetic joint infection (PJI)
Zareprumig: Treatment of multiple sclerosis (MS)
September 2026
Asedebart: Treatment of conditions characterized by chronically elevated adrenocorticotropic hormone (ACTH)
Copper Cu 64 Abefolastat Tesaroxetan: Diagnostic agent, oncology
Dalretapopt: Treatment of advanced solid tumors harboring TP53 Y220C mutation
Dipalmitoyl hydroxyproline: Treatment of Netherton Syndrome (NS)
Duvobotgene erpavec: Gene therapy for the treatment of urinary incontinence
Felcorekibart: Treatment of adult and pediatric patients aged 12 years and older with asthma
Filimelnotide: Treatment of rare genetic, syndromic, and acquired diseases of obesity such as hypothalamic obesity (HO), and other obesities caused by deficiencies within the MC4R pathway
Filimelnotide hydrochloride: Treatment of rare genetic, syndromic, and acquired diseases of obesity such as hypothalamic obesity (HO), and other obesities caused by deficiencies within the MC4R pathway
Mocertatug rezetecan: Antineoplastic
Grebenpepimut simolenin alfa: Treatment of cancer
Grivamisulpride: Treatment of schizophrenia
Insulin eftuxvet: Treatment of feline (cat) diabetes
Melurotogene parvec: Treatment of OTOF-related congenital hearing loss
Pinverasib: Antineoplastic
Rezetecan: Treatment of advanced solid tumors
Sunakiment: Treatment of asthma and obstructive airway diseases
Tanerasertib: Antineoplastic, treatment of advanced solid tumors with the AKT1 E17K mutation
Tanerasertib maleate: Antineoplastic, treatment of advanced solid tumors with the AKT1 E17K mutation
Tegacorat: Treatment of inflammatory diseases
Tirgadisgene parvec: Treatment of Duchenne muscular dystrophy (DMD) in patients with confirmed mutations in the dystrophin gene
Ubletamig: Antineoplastic, treatment of ovarian cancer and MUC16-expressing cancers
Umiposgene parvec: Treatment of heart failure (HF)
August 2026
Adimanebart: Treatment of neuromuscular diseases with impaired neuromuscular junction (NMJ) function
Arumakimig: Anti-inflammatory
Claseprubart: Treatment disorders driven by the complement pathway (CP) cascade
Cleminorexton: Treatment of narcolepsy
Emrusolmin: Treatment of multiple system atrophy (MSA)
Mirivadelgat: Treatment of Fanconi anemia (FA)
Mirivadelgat hydrochloride: Treatment of Fanconi anemia (FA)
Mocertatug: Antineoplastic
Mocertatug rezetecan: Antineoplastic
Nucresiran: Treatment of transthyretin (TTR)-mediated amyloidosis (ATTR Amyloidosis)
Nucresiran sodium: Treatment of transthyretin (TTR)-mediated amyloidosis (ATTR Amyloidosis)
Pilabactam: Treatment of complicated urinary tract infections (cUTI), hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), and complicated intraabdominal infections (cIAI)
Pimurutamab: Treatment of advanced solid tumors
Risvutatug: Antineoplastic
Risvutatug rezetecan:
Utreglutide: Treatment of Type II diabetes in obese or overweight patients with comorbidities
Velzatinib: Treatment of unresectable and/or metastatic gastrointestinal stromal tumors
Vormatrigine: Treatment of adult focal onset epilepsy
Zilovertamab vedotin: Antineoplastic
Zolucatetide: Treatment of advanced and/or metastatic solid tumors